WBSCR27 Inhibitors
WBSCR27 inhibitors are a category of chemical compounds that specifically target and inhibit the activity of the enzyme WBSCR27. The enzyme itself is part of a larger family of proteins that play crucial roles in various biochemical pathways within the cell. WBSCR27, like other members of its family, is involved in complex cellular processes that are fundamental to maintaining cellular homeostasis and function. The inhibitors designed to target WBSCR27 are typically small molecules that can bind to the active site of the enzyme or to other critical regions important for its activity. By doing so, these inhibitors effectively reduce or block the enzyme's action.
The design and development of WBSCR27 inhibitors require a deep understanding of the enzyme's structure and the precise mechanisms by which it interacts with its substrates and other cellular components. Researchers utilize a range of techniques, including X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling, to determine the three-dimensional conformation of WBSCR27 and to identify potential binding sites for inhibitors. The chemical structure of WBSCR27 inhibitors is often fine-tuned through iterative processes of synthesis and testing, allowing for the optimization of their binding affinity and specificity. These inhibitors are the result of sophisticated medicinal chemistry efforts aiming to modulate the function of WBSCR27 for studies that advance our comprehension of the enzyme's role at the molecular and cellular level.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that suppresses mTORC1 activity. WBSCR27 is involved in pre-rRNA processing, which is a downstream process influenced by mTORC1 signaling. Inhibition of mTORC1 by Rapamycin can lead to reduced WBSCR27 activity due to diminished ribosome biogenesis. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
A transcription inhibitor that binds to DNA and prevents RNA synthesis. By inhibiting transcription, Actinomycin D can decrease the expression of WBSCR27, as it inhibits the gene transcription machinery necessary for WBSCR27 synthesis. | ||||||
Leptomycin B | 87081-35-4 | sc-358688 sc-358688A sc-358688B | 50 µg 500 µg 2.5 mg | $107.00 $416.00 $1248.00 | 35 | |
An inhibitor of nuclear export that binds to exportin 1 (CRM1), preventing the nuclear export of proteins and RNA complexes. WBSCR27 function could be indirectly impaired due to disruptions in proper nuclear-cytoplasmic trafficking required for its function. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
A diterpene triepoxide that inhibits RNA polymerase II activity, leading to reduced transcription. This would result in decreased levels of WBSCR27 due to lower mRNA synthesis for the protein. | ||||||
CX-5461 | 1138549-36-6 | sc-507275 | 5 mg | $245.00 | ||
A selective RNA Polymerase I inhibitor, which leads to the disruption of rRNA synthesis and ribosome biogenesis. Inhibition of Pol I can indirectly lead to decreased WBSCR27 function as it is linked to pre-rRNA processing. | ||||||
Spliceostatin A | 391611-36-2 | sc-507481 | 1 mg | $1800.00 | ||
A compound that inhibits splicing by binding to the spliceosome, potentially reducing the maturation of pre-mRNA to mRNA. This may lead to a decrease in mature mRNA and consequently lower levels of WBSCR27. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
An autophagy inhibitor that raises lysosomal pH, affecting autophagosome fusion. Since autophagy is a cellular recycling process, its inhibition could result in decreased degradation of dysfunctional WBSCR27, potentially affecting its turnover and function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that prevents degradation of ubiquitinated proteins. By inhibiting the proteasome, Bortezomib could lead to an accumulation of misfolded or damaged WBSCR27 proteins, indirectly affecting WBSCR27 function. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
An inhibitor of the spliceosome, specifically targeting the SF3b complex, affecting mRNA splicing. This could reduce the availability of properly spliced WBSCR27 mRNA, leading to a decrease in WBSCR27 protein levels. | ||||||
Homoharringtonine | 26833-87-4 | sc-202652 sc-202652A sc-202652B | 1 mg 5 mg 10 mg | $52.00 $125.00 $182.00 | 11 | |
A cephalotaxine ester that inhibits protein synthesis by preventing the initial elongation step of translation. Reduced protein synthesis would, therefore, result in lower levels of WBSCR27. | ||||||